LabGenomics Signs Agreement to Acquire Clia Lab... "Initiating Second Lab Acquisition"
LabGenomics announced on the 27th that it has signed an acquisition agreement for QDx Pathology Services, a US top 100 CLIA lab with sales of approximately 70 billion KRW.
The company stated that, as the first in the domestic diagnostics industry to successfully acquire a mid-to-large scale US CLIA lab, it will innovatively transform the diagnostic ecosystems of both Korea and the United States. In particular, through the CLIA lab, it is expected to serve as a foothold for entering the US market by providing products from domestic diagnostic companies with excellent technological capabilities. The acquisition price is 76.8 billion KRW.
A LabGenomics representative said, "Since the end of last year, we have been reviewing acquisitions of multiple CLIA labs, and recently carefully selected the first target lab for acquisition. We chose a lab not only for its own attractiveness but also for its potential to create the greatest synergy with our company, and we plan to immediately start the acquisition of the second lab."
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
CLIA labs can supply diagnostic services and products that have not been approved by the FDA (Food and Drug Administration) locally in the US. The competitiveness of CLIA labs lies in their insurance sales networks, and acquiring a CLIA lab with such networks allows for faster achievement of meaningful performance.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
